Kathy Williams, Ph.D. Quoted on Licensing CRISPR Technology in BioCenturyPrint PDF
Kathy Williams, Ph.D., a partner in Nutter’s Intellectual Property Department and co-chair of the firm’s Life Sciences practice group, commented on the ongoing CRISPR IP litigation in BioCentury. In the article, “No Crisp Upper Hand in CRISPR,” Kathy notes that for companies seeking to license, the safest course may be to license intellectual property from both sides. According to Kathy, either licensing or infringing the intellectual property could be expensive, raising the possibility of increased drug prices down the line.